


Editorial

Lipidology: A New Open Access Journal

Nicola Ferri 

Department of Medicine, University of Padova, Campus Biomedico Pietro D'Abano, Via Giuseppe Orus 2B, 35131 Padova, Italy; nicola.ferri@unipd.it

On behalf of all the Editorial Board members and MDPI staff, I am pleased to announce the publication of the inaugural issue of the *Lipidology* journal [1] (ISSN: 2813-7086), a peer-reviewed and open access online journal that aims to become the publishing platform of choice for all researchers researching lipids. We believe that a journal centred on lipidology is essential for gathering and spotlighting cutting-edge advances in the study of all types of lipids, such as fatty acids, triglycerides, glycerophospholipids, sphingolipids, and steroids. All of these molecules play fundamental roles in human physiology, and their dysregulation is associated with neurodegenerative, cardiovascular, genetic, liver, and kidney diseases, as well as many rare diseases. *Lipidology* will collect original research, review papers, communications, perspectives, opinions, and technical notes, as well as publish Special Issues on the different scientific disciplines related to lipids, such as chemistry, biochemistry, biotechnology, pharmacology, nutrition, metabolism, and clinical science (Figure 1).



Citation: Ferri, N. *Lipidology*: A New Open Access Journal. *Lipidology* **2024**, *1*, 1–2. <https://doi.org/10.3390/lipidology1010001>

Received: 18 February 2024

Accepted: 19 February 2024

Published: 1 March 2024



Copyright: © 2024 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

Figure 1. Lipids and their relevance in preclinical and clinical sciences.

The recent development of new technologies to determine the complete lipid profile (lipidome) within a cell, tissue, organism, or ecosystem has been a vital step forward in defining the biochemical mechanisms of lipid-related disease processes via the identification of alterations in cellular lipid metabolism, trafficking, and homeostasis. A complete

understanding of lipid metabolism and its alteration in different lipid-related pathologies is crucial for the development of new pharmacological interventions. One key example in this field is represented by the class of drugs that are currently used for the treatment of atherosclerotic coronary artery diseases and that affect lipid metabolism—statins, fibrates, and PCSK9 and ANGPTL3 inhibitors. However, many other diseases that are also associated with lipid dysmetabolism require further investigation for drug development, including neurovegetative diseases. Furthermore, lipids are essential components of our diet, and numerous studies have demonstrated the effectiveness of healthy dietary patterns and lifestyles for the prevention of cardiovascular diseases. Our journal is thus open to researchers involved in nutritional intervention and epidemiological studies related to lipid consumption and human health. Finally, lipids are important biotechnological tools for mRNA delivery, as observed for lipid nanoparticles (LNPs) utilized in mRNA-based vaccines to prevent SARS-CoV-2, the cause of COVID-19. This field is extremely important for the development of new drug delivery systems that have the potential to improve the efficacy, safety, and compliance of biotechnological therapies, such as siRNA, monoclonal antibodies, and recombinant proteins.

The editors, Editorial Board, and publisher invite you to submit your work to this journal and join us as we develop a community of multidisciplinary researchers in the field of lipidology. We hope that you will consider *Lipidology* as the journal of choice for your research, and we look forward to collaborating with you.

Conflicts of Interest: The author declares no conflicts of interest.

Reference

1. *Lipidology* Home Page. Available online: <https://www.mdpi.com/journal/lipidology> (accessed on 14 February 2024).

Short Biography of Author



Prof. Dr. Nicola Ferri is a distinguished Italian pharmacologist currently holding the position of Full Professor in Pharmacology at the Department of Medicine, University of Padua. He earned his master's degree in Pharmaceutical and Chemistry Technologies from the University of Milan in 1996, achieving "Magna cum Laude" status. His academic journey continued with Ph.D. degrees in 2002 at the same institution, along with a master's degree in Pharmacy and Oncological Pharmacology (2006). Prof. Dr. Ferri boasts an extensive research career, including postdoctoral positions at the University of Milan's Department of Pharmacological and Biomolecular Sciences and a notable stint as a visiting scientist at the University of Washington in Seattle, USA, under Dr. Elaine Raines. From 1999 to 2003, he served as a senior research fellow at the Department of Pathology, School of Medicine, University of Washington, Seattle. In 2018, Prof. Dr. Ferri assumed the role of Associate Professor in Pharmacology at the University of Padua, further ascending to Full Professor in 2021.

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.